What Is the MPL Adjuvant and How Does It Work?

Monophosphoryl lipid A, commonly called MPL, is a chemically detoxified fragment of the bacterial molecule lipopolysaccharide (LPS) that retains the ability to stimulate the immune system without causing the dangerous inflammatory reactions that LPS itself triggers. It works by activating a specific receptor on immune cells called Toll-like receptor 4 (TLR4), which kicks off a cascade that strengthens both the immediate and long-lasting arms of the immune response to a vaccine. Since its development in the 1980s, MPL has become one of the most widely used modern vaccine adjuvants, appearing in licensed vaccines against hepatitis B, human papillomavirus, malaria, shingles, and respiratory syncytial virus.

Where MPL Comes From

MPL traces back to a bacterium called Salmonella minnesota R595, a rough mutant strain whose outer membrane contains a simplified form of LPS. LPS is the molecule responsible for much of the fever and shock associated with bacterial infections, so using it directly in a vaccine would be out of the question. In the early 1980s, researcher Edgar Ribi figured out how to strip away the most toxic parts of LPS while keeping the portion that alerts the immune system.¹ The result was monophosphoryl lipid A, which has one fewer phosphate group than the parent molecule and a modified pattern of fatty acid chains. Purification of the material from Salmonella yields a mixture of forms with different numbers of fatty acid chains, primarily the hexaacyl (six-chain) version, which turned out to be the most immunologically active.²

How MPL Activates the Immune System

The core of MPL’s mechanism is its interaction with TLR4, a receptor found on the surface of immune cells like macrophages and dendritic cells. When MPL binds TLR4, it sets off intracellular signaling pathways that tell the cell an infection-like threat is present. But here is the critical difference from full LPS: MPL preferentially activates one of the two major signaling branches downstream of TLR4, a pathway mediated by an adapter protein called TRIF. The other branch, mediated by a protein called MyD88, is the one most responsible for the aggressive, sometimes dangerous inflammatory response to LPS. Research in mice showed that MPL’s low toxicity is specifically linked to this TRIF bias, and that the suppression of the MyD88 pathway is an active process rather than a simple loss of function.³

This selectivity matters because the TRIF pathway still triggers the immune-boosting effects a vaccine needs. It drives the production of type I interferons and other signaling molecules that help immune cells mature and present antigens more effectively, without unleashing the surge of pro-inflammatory molecules that causes fever, tissue damage, and the potential for septic shock.

What MPL Does to Immune Cells

Once MPL engages TLR4, its most immediate visible effect is on dendritic cells, which are the immune system’s professional scouts. In mouse studies, administering MPL caused dendritic cells to mature rapidly and migrate to areas of the spleen where T cells congregate, putting them in position to present vaccine antigens and trigger a targeted immune response.⁴ MPL also boosts macrophage activity, increasing their production of a signaling molecule called IL-12 and their surface expression of a co-stimulatory molecule called B7-1, both of which are important for pushing T cells toward a particular flavor of immune response.⁵

That particular flavor is the Th1 response. The immune system can lean toward different types of helper T cell activity: Th1 responses are especially good at fighting intracellular pathogens and viruses, while Th2 responses are better at handling parasites and are associated with antibody-heavy immunity. Many traditional adjuvants, like aluminum salts, tend to push toward Th2. MPL pushes toward Th1, which is one of the main reasons vaccine designers find it so valuable. Research using an HIV protein as a test antigen showed that adding MPL to a formulation shifted the T cell response from Th2-dominated to Th1-dominated, with T cells producing the kinds of cytokines associated with strong cellular immunity.⁵

The Adjuvant Systems Built Around MPL

MPL is rarely used alone in licensed vaccines. Instead, it has been combined with other ingredients to create what GSK (GlaxoSmithKline) calls “Adjuvant Systems,” each designed for a different kind of immune challenge.

The most straightforward combination is AS04, which pairs MPL with an aluminum salt. The aluminum does not directly amplify MPL’s activity in a synergistic way; rather, it prolongs the duration of MPL’s local immune-stimulating effects at the injection site. By keeping MPL around longer, the aluminum gives antigen-presenting cells more time to become fully activated, which leads to a stronger adaptive immune response downstream.⁶ AS04 is used in the hepatitis B vaccine Fendrix and the HPV vaccine Cervarix.

The more complex combination is AS01, which pairs MPL with a saponin called QS-21 in a liposome formulation. This pairing produces a genuine synergy that neither component achieves on its own. Within hours of injection, MPL and QS-21 together cause resident immune cells in the draining lymph node, including natural killer cells and CD8+ T cells, to release the signaling molecule interferon-gamma (IFNγ). This early IFNγ burst, controlled by macrophages and the cytokines IL-12 and IL-18, turns out to be essential for the activation of dendritic cells and the development of strong Th1 immunity.⁷ AS01 is the adjuvant in the shingles vaccine Shingrix and the malaria vaccine Mosquirix.

Vaccines That Use MPL-Based Adjuvants

The practical reach of MPL is broad. It now appears in vaccines targeting several very different diseases, and in some cases it has made vaccines possible for targets where earlier attempts failed.

The HPV vaccine Cervarix, formulated with AS04, demonstrated high and sustained immune responses in women aged 15 to 55. At four years after vaccination, all subjects remained seropositive for anti-HPV-16 antibodies, and antibody levels stayed several-fold above what natural infection produces, even in women over 45.⁸ Follow-up extending to roughly eight years showed vaccine efficacy of about 95% against incident HPV-16/18 infection, with all vaccinated women remaining seropositive and antibody titers staying well above natural infection levels throughout.⁹

The malaria vaccine Mosquirix (RTS,S/AS01) is a landmark case. Malaria parasites are notoriously difficult targets for vaccines because they have complex life cycles and highly variable surface proteins. Mosquirix offers modest but meaningful protection, particularly for young children in high-transmission areas where mortality is greatest.¹⁰ A meta-analysis of malaria vaccine trials found that RTS,S/AS01 provided roughly a 39% reduction in malaria risk in children aged five to seventeen months, though efficacy declined over time, underscoring the importance of booster doses.¹¹ For the youngest age group (six to twelve weeks), the risk reduction was about 23%. Even this modest effect translates into thousands of prevented cases in regions where malaria kills hundreds of thousands of children each year.

The shingles vaccine Shingrix, also formulated with AS01, is widely considered one of the most effective vaccines in older adults, a population that typically responds poorly to vaccination because of immune aging. Recent research has shed light on why: vaccination with the AS01-adjuvanted vaccine selectively enhances Th17 CD4+ T cells, a type of helper cell that compensates for age-related declines in CD8+ T cell function. The vaccine did not restore CD8+ defects, but the Th17 boost was enough to maintain durable protection.¹²

Building Lasting Immune Memory

One of the most important contributions MPL makes to a vaccine is not just the strength of the initial immune response but how long protection persists. When MPL was added to an aluminum-adjuvanted HPV formulation to create AS04, the resulting vaccine generated roughly two to five times more antigen-specific memory B cells compared to formulations using aluminum alone.¹³ Memory B cells are the long-lived sentinels that allow the immune system to mount a rapid antibody response if it encounters the pathogen again years later.

On the T cell side, research demonstrated that combining aluminum salts with MPL could prime long-lived memory CD8+ T cells capable of protecting mice from viral challenge. Aluminum alone generated memory CD8+ T cells, but those cells did not develop effective killing capacity. Adding MPL was the ingredient needed for proper cytotoxic T cell differentiation.¹⁴ When combined with another adjuvant called Poly I:C, MPL also boosted both central memory and effector memory T cell populations in lung tissue, suggesting potential value for vaccines targeting respiratory infections.¹⁵

Safety Profile

The whole point of MPL’s existence is that it retains the immune-activating properties of LPS while shedding the toxicity. Formal safety evaluations have borne this out. Repeat-dose toxicity studies in rats and dogs showed the kinds of effects you would expect from an immune stimulant, such as increased spleen weight and elevated white blood cell counts, but no unexpected organ toxicity. Studies in rabbits given weekly doses produced no adverse effects at all. MPL showed no negative effects on cardiovascular or respiratory function, no reproductive toxicity, and no genotoxicity.¹⁶

In the context of licensed vaccines, the safety record of MPL-containing adjuvants has been evaluated across millions of doses. The most common side effects are the same localized reactions seen with most vaccines: pain, redness, and swelling at the injection site, sometimes accompanied by mild fatigue or fever. These reflect the adjuvant doing its job, transiently activating the local immune environment, and they resolve within a day or two.

Synthetic Alternatives and Next-Generation Versions

One limitation of traditional MPL is that it comes from a biological source, which means the final product is a mixture of slightly different molecular species rather than a single pure compound. The manufacturing process involves extracting and chemically modifying LPS from bacterial cultures, which is expensive and labor-intensive.¹⁷ This has driven two parallel efforts to create better-defined versions.

The first is glucopyranosyl lipid adjuvant, or GLA, a fully synthetic hexaacylated lipid A molecule. Because GLA is produced through chemical synthesis, every batch is identical, eliminating the variability inherent in biological extraction. Testing showed that GLA has immunomodulatory activity similar to naturally derived MPL on mouse dendritic cells, including cytokine production and dendritic cell maturation, and was actually more potent on a molar basis when tested on human dendritic cells and blood cells.¹⁸ In animal studies, GLA delivered intranasally proved to be a powerful mucosal adjuvant, significantly boosting both systemic and mucosal antibody responses and inducing higher levels of IgA, the antibody class most important for protection at mucosal surfaces, compared to other adjuvants tested alongside it.¹⁹

The second approach uses metabolic engineering. Researchers have engineered E. coli strains to produce and accumulate MPL directly inside the bacteria, bypassing both chemical synthesis and the need to extract from Salmonella. The purified product stimulated antigen-specific antibody responses in mice comparably to commercial MPL, but with dramatically reduced manufacturing time and cost.¹⁷ If this technology scales, it could make MPL-based adjuvants far more accessible for vaccines in lower-income countries, where cost is a major barrier.

Uses Beyond Infectious Disease Vaccines

MPL’s ability to steer the immune system toward Th1 responses has attracted interest well beyond conventional vaccines. In allergy immunotherapy, formulations combining modified allergens (allergoids) with MPL adsorbed onto microcrystalline tyrosine have been used to treat IgE-mediated allergies. The idea is that MPL’s Th1 push can help rebalance the immune response away from the Th2-dominated, IgE-heavy pattern that drives allergic disease.²⁰

Cancer immunotherapy is another active area of exploration. Since effective anti-tumor immunity depends heavily on cytotoxic T cells and Th1 helper cells, the same properties that make MPL useful in vaccines against infections apply to therapeutic cancer vaccines. The adjuvant has been investigated in formulations designed to train the immune system to recognize and attack tumor antigens.²¹ This remains a challenging field, as tumors have multiple ways of suppressing immune responses, but MPL’s track record of safety and its proven ability to promote cellular immunity make it a plausible component of future therapeutic combinations.

How MPL Compares to Aluminum Salts Alone

Aluminum-based adjuvants (often just called “alum”) have been used in vaccines for nearly a century and remain the most common adjuvants worldwide. They work well for generating antibody responses, but they predominantly drive Th2-type immunity, which is not ideal for every pathogen. For diseases like pertussis, where protection depends on a more balanced T-helper profile or even a Th1-leaning response, aluminum alone may fall short. Preclinical work comparing the combination of aluminum hydroxide with MPL against aluminum alone for pertussis-type vaccines confirmed that adding the TLR4 agonist shifted the immune profile in a direction that could better protect against the actual pathogen.⁶

The HPV vaccine data illustrate this concretely. When AS04 (aluminum plus MPL) was compared against aluminum-only formulations, the AS04 version generated not only higher antibody titers but also a two- to fivefold greater frequency of memory B cells specific to the HPV antigens.¹³ That difference in memory B cells is likely a key reason why the Cervarix vaccine maintains high antibody levels years after vaccination, well above what natural infection would produce. The added cost and complexity of including MPL has a tangible payoff in immune durability.

MPL in Vaccines for Older Adults

Immune aging, sometimes called immunosenescence, is one of the biggest challenges in vaccinology. As people get older, their immune systems become less responsive to vaccination, which is why diseases like shingles and influenza hit older adults hardest. The success of Shingrix in adults over 50 made the vaccine community pay attention to what AS01 was doing that other adjuvants could not.

The mechanism appears to involve a workaround rather than a reversal of immune aging. Older adults vaccinated with the AS01-adjuvanted shingles vaccine showed selective enhancement of Th17 CD4+ T cells specific to the varicella-zoster virus antigen. These Th17 cells were also resistant to conversion into regulatory T cells, which normally dampen immune responses and increase with age. The net result was durable vaccine-induced immunity that compensated for the decline in CD8+ T cell function typical of aging, without needing to fix the CD8+ problem directly.¹² This finding has implications beyond shingles: if MPL-containing adjuvants can reliably engage Th17 pathways in older adults, they could improve vaccine performance across a range of diseases that disproportionately affect the elderly.